Amneal to close it Hayward, California-based facilities and operations

25 May 2018

Company to streamline operations and capture cost synergies.

Amneal Pharmaceuticals is to streamline operations following a comprehensive analysis of its current and future product portfolios, plant capacities, overlapping capabilities and cost structure as a result of the recent business combination with Impax Laboratories. As a result, the company will close its Hayward, California-based facilities and operations.

Amneal to close it Hayward, California-based facilities and operations

The company will immediately implement plans to phase out the Hayward facilities with an expected completion timeline of approximately 15 months, nearly one-year ahead of schedule. Amneal expects to transfer products manufactured at the Hayward facility to the company's lower-cost facilities in the US and India.

"We are taking these steps to streamline our operations, accelerate savings and generate resources to drive organic growth as well as pursue external growth opportunities," said Rob Stewart, President and CEO of Amneal. "The acceleration of these initiatives primarily in manufacturing and R&D operations, combined with our large and diverse generic pipeline of potential high-value product opportunities, will help us achieve our commitment to generate approximately $1.1 billion of adjusted EBITDA by the end of 2020. Our announcement is not expected to materially impact our full year 2018 adjusted EBITDA guidance of $600 million to $650 million and full year adjusted EPS of $0.95 to $1.10 per diluted share. We do expect a significant favorable impact beginning in 2019."

Mr Stewart continued: "I recognize that these types of announcements are difficult for our colleagues. We have announced and are committed to implementing a comprehensive transition plan. We will also work toward an orderly wind-down of the Hayward facilities to ensure these actions cause minimal disruptions to customers and patients. I have asked teams across our company for their full support of our colleagues in Hayward as we work together through this difficult transition."

Amneal expects the facility closures to reduce its workforce by approximately 550 positions. Additional details regarding the financial impact and pre-tax restructuring charges will be provided in a future company filing.

Read More

Related news

New portable and ready-to-use upper respiratory drug delivery solution

New portable and ready-to-use upper respiratory drug delivery solution

11 Oct 2018

PureHale is valuable to pharmaceutical partners seeking a system that can carry a range of formulations and comes in various container sizes.

Read more 
CPhI Worldwide announces the winners  of the 15th Pharma Awards

CPhI Worldwide announces the winners of the 15th Pharma Awards

10 Oct 2018

17 winners chosen from over 250 entries, with Nanobiotix winning both ‘CEO‘ and ‘Pharma Company of the Year’ categories.

Read more 
CMOs to benefit from double digit approvals for ADCs in the next 3 years

CMOs to benefit from double digit approvals for ADCs in the next 3 years

9 Oct 2018

Therapeutic ADC market expected to reach $4 billion by 2023.

Read more 
Micro-Sphere increases capsule filling capacity

Micro-Sphere increases capsule filling capacity

8 Oct 2018

The MG2 Tekna increases the CDMO’s manufacturing capacity to up to 500 million capsules per year.

Read more 
Symbiosis secures FDA viral vector process approval

Symbiosis secures FDA viral vector process approval

5 Oct 2018

Strengthens the CDMO's position as a centre of excellence as part of the viral vector drug development supply chain.

Read more 
Three-way collaboration to advance gene therapy

Three-way collaboration to advance gene therapy

4 Oct 2018

Partnership aims to increase the robustness and reduce costs for the manufacturing of AAV vectors.

Read more 
New horizontal flow wrapping machine for hermetic packages

New horizontal flow wrapping machine for hermetic packages

3 Oct 2018

Greater product protection thanks to reliable sealing technologies.

Read more 
Movement on the market reflected at CPhI Worldwide 2018

Movement on the market reflected at CPhI Worldwide 2018

3 Oct 2018

Companies new to CPhI to showcase an exciting range of products and services ranging from electroceuticals to refrigerant alternatives.

Read more 
Niche CDMO confirms spray drying for highly potent drugs

Niche CDMO confirms spray drying for highly potent drugs

1 Oct 2018

Idifarma's GMP spray drying technology for highly potent drugs up to Category 4 OEL/OEB is now operational.

Read more 
Custom scalable turnkey PODs for flexible continuous bioprocess and viral vector facility solutions

Custom scalable turnkey PODs for flexible continuous bioprocess and viral vector facility solutions

1 Oct 2018

The PODs ease verification, qualification and validation challenges, and their flexibility allows them to support multiple products.

Read more